head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2018, vol. 24, issue2
Subject Area: Medicine
DOI: 10.5272/jimab.2018242.1998
Published online: 31 May 2018

Original article

J of IMAB. 2018 Apr-Jun;24(2):1998-2001
Tsvetomir Dimitrov1ORCID logo Corresponding Autoremail, Tsvetelina Mihaylova2ORCID logo, Desislava Todorova3ORCID logo,
1) Department of Health Care, Faculty of Public Health, Medical University of Sofia, Bulgaria,
2) Department of Medical Pedagogy, Faculty of Public Health, Medical University of Sofia, Bulgaria,
3) Department of Preventive Medicine, Faculty of Public Health, Medical University of Sofia, Bulgaria.

The eye diseases cause sufferings, affect the quality of life of the patient, and decrease the level of his/her well-being. The disability, related to the diminution of vision, is an indicator for the medical condition of the population, state of morality and ethics in the society, and it may be corrective in the work of healthcare professionals. The aim of the study is an analysis of the significance and extent of the problem with reference to the quality of life of patients with poor vision. The task is an exploration of the quality of life in connection with eye disability, which to assist in selecting appropriate measures regarding the problem. The glaucoma is a serious, socially significant disease, which may lead to considerable loss of vision and to blindness if let untreated. A study of the primary disability during the period from the year 2005 to 2012, in Eastern Bulgaria, demonstrated that the glaucoma is a leading cause of bilateral blindness. The degree of vision reduction causes a considerable impact on the quality of life. The factor age influences negatively the quality of life in patients with loss of vision. The poorest quality of life (QoL) had the oldest, and the persons below 40 years of age. The assessment of the disability, and of the worsened QoL for patients with eye diseases and their families, as well as for the Bulgarian society, is of primary significance for the creation of positive practices as performing of screening programs, etc.

Keywords: quality of life, loss of vision, glaucoma, disability,

pdf - Download FULL TEXT /PDF 492 KB/
Please cite this article as: Dimitrov Ts, Mihaylova Ts, Todorova D. Quality of life of patients with diminished vision. J of IMAB. 2018 Apr-Jun;24(2):1998-2001. DOI: 10.5272/jimab.2018242.1998

Corresponding AutorCorrespondence to: Tsvetomir Dimitrov, Clinical Department of Ophthalmology, First General Hospital for Active Treatment Sofia AD; 37, Patriarch Evtimiy Blvd., 1000 Sofia, Bulgaria; E-mail: tsdimitrov.or@gmail.com,

1. Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013 Dec;1(6):e339-49. [PubMed] [CrossRef]
2. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008. Eye (Lond). 2010 Nov;24(11):1692-9. [PubMed] [CrossRef]
3. Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin Ther Pat. 2012 Jan;22(1):79-88. [PubMed] [CrossRef]
4. European Glaucoma Society: Terminology and Guidelines for Glaucoma. Savona, Publicomm, 2014: 75-127.
5. Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Expert Opin Pharmacother. 2014 Aug;15(12):1737-47. [PubMed] [CrossRef]
6. Hommer A. Role of fixed combinations in the management of open-angle glaucoma. Expert Rev Pharmacoecon Outcomes Res. 2011 Feb;11(1):91-99. [PubMed] [CrossRef]
7. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007 Nov;114(11):1965-72. [PubMed] [CrossRef]
8. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005 Jul 16;331(7509):134. [PubMed] [CrossRef]
9. Owen CG, Carey IM, De Wilde S, Whincup PH,Wormald R, Cook DG. The epidemiology of medicaltreatment for glaucoma and ocular hypertensionin the United Kingdom: 1994 to 2003. Br J Ophthalmol. 2006 Jul;90(7):861-8. [PubMed] [CrossRef]
10. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J< Ophthalmol. 2006 Mar;90(3):262-7. [PubMed] [CrossRef]
11. Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence. 2011; 5:441-463. [PubMed] [CrossRef]
12. Rouland JF, Le Pen C; Ophthalmologists of the Glaucoma Study. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year. Eur J Ophthalmol. 2003 Jul;13 Suppl 4:S5-20. [PubMed]
13. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081-2090. [PubMed] [CrossRef]
14. Nenkova B. Demographic changes and visual disability in Eastern Bulgaria. Scripta Scientifica Medica. 2015; 47(3):43-47
15. Nenkova B, Pandova M. Trends in Registered blindness in Eastern Bulgaria. Scripta Scientifica Medica. 2014; 46(4):9-21
16. Nencheva B. [Blindness and poor vision in Eastern Bulgaria - a modern approach.] [Dissertation] MU - Varna. 2014. 111 p. [in Bulgarian].

Received: 11 December 2017
Published online: 31 May 2018

back to Online Journal